title: Health assessment questionnaire score is the best predictor of 5-year quality of life in early rheumatoid arthritis.
abstract: OBJECTIVE
  To evaluate and determine prognostic factors of 5-year quality of life in patients with early rheumatoid arthritis (RA).
  
  
  METHODS
  A cohort of 191 patients with RA and disease duration < 1 year was prospectively followed over 5 years. The outcome measure was quality of life as assessed by the Arthritis Impact Measurement Scales 2 (AIMS2). Univariate analysis, then stepwise multiple logistic regression, was used to find independent baseline prognostic variables.
  
  
  RESULTS
  After accounting for death, loss of followup, and missing data, 158 patients (82.72%) were included in the analysis. The mean AIMS2 physical, symptom, psychological, social interaction, and work scores after 5 years were 1.6 (range 0-6.88), 4.0 (0-10), 3.48 (0-9.22), 4.06 (0-8.69), and 1.87 (0-8.13), respectively. The AIMS2 physical component was significantly correlated with Health Assessment Questionnaire (HAQ) score at 5 years. Logistic regression analysis revealed that the baseline values able to predict the 5-year physical, psychological, symptom, social interaction, and work status were, respectively: HAQ score and erythrocyte sedimentation rate (ESR), body mass index (BMI), HAQ; erosion score and sex, HAQ; ESR and anti-perinuclear antibody; matrix metalloproteinase-3 (MMP3) level, joint space narrowing, and tender joint scores; HAQ score and age.
  
  
  CONCLUSIONS
  The multidimensional structure of the AIMS2 allowed us to assess the 5-year health-related quality of life in early RA. Using this instrument as an outcome variable, prognostic factors were selected and varied widely depending on the evaluated domain. The baseline HAQ score was the best predictive factor of 4 of the 5 domains of the AIMS2.
authors.affiliation: Department of Immuno-Rhumatologie, CHU Montpellier, Montpellier I University and INSERM U454, Montpellier, France.
authors.forename: Jean-David
authors.initials: JD
authors.lastname: Cohen
authors.forename: Maxime
authors.initials: M
authors.lastname: Dougados
authors.forename: Philippe
authors.initials: P
authors.lastname: Goupille
authors.forename: Alain
authors.initials: A
authors.lastname: Cantagrel
authors.forename: Olivier
authors.initials: O
authors.lastname: Meyer
authors.forename: Jean
authors.initials: J
authors.lastname: Sibilia
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Daurès
authors.forename: Bernard
authors.initials: B
authors.lastname: Combe
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000523:psychology*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D011788:Quality of Life; D011859:Radiography; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents